Financial Analysis of Medassets Term Paper

Pages: 8 (2111 words)  ·  Bibliography Sources: 10  ·  File: .docx  ·  Level: Master's  ·  Topic: Business

Financial Analysis of MedAssets

Company Overview

MedAssets Inc. is an organization that provides technology enabled product and service to mitigate the financial instability facing the healthcare providers across the United States. The company has assisted many healthcare organizations to increase their net revenue between 1 and 3% and decline the costs by 3 to 10%. Through the company efficient operation, MedAssets has assisted 4,000 hospitals, 180 health systems and 90,000 non-acute healthcare providers to control costs and optimize operational efficiency. The company was incorporated in 1999 with headquarter in Alpharetta in Georgia. Typically, the company provides a streamlined solution to improve the operating margin and cash flow of many healthcare providers in the United States.

"Over time, MDAS has evolved into a comprehensive health care technology and services provider. This transition was fueled by organic initiatives and a strategic series of acquisitions. Currently, MDAS offers hospitals and other health care providers value through solutions geared towards revenue, profitability, and cash flow enhancement." (Donohue, 2009 P. 1)

Get full Download Microsoft Word File access
for only $8.97.
MedAssets uses the technology-enable solution to implement consulting and outsourcing service for wide range of healthcare providers across the country. Through company business activity, MedAssets has been able to increase its total revenue in the last 5 years. The company increases its total revenue from $391 Million at the end of the 2010 fiscal year to $578 Million in 2011. Despite the increase in the revenue in the last 5 years, the company suffered a decline in the net income at the end of the 2010 and 2011 fiscal years. In 2009, the company recorded $20 Million in net income, however, the company recorded a loss of $32 Million in net income at the end of the 2010 fiscal year and $15 million net income loss at the end of 2011 fiscal year. With a decline in net income, MedAssets recorded a decline in the stock performances from $20.19 to $9.25 between 2010 and 2011

Term Paper on Financial Analysis of Medassets Assignment

The objective of this report is to discuss the strategy MedAssets implements to use the financial instruments such as stocks, and derivatives. The report provides the historical price of MedAssets to enhance greater understanding of MedAssets stock performances in the last 5 years.

Historical Overview of MedAssets Stock

Historical stock performances are a good guide that reveals the past performances of a company and provides a guide on the future stock performances of a company. In the last 5 years, MedAssets stock performances have not been stable. In 2007, the company stock improved tremendously where the stock price reached $23.94. Since 2007, the company stock price has declined in value. The illustration in the Fig 1 reveals the stock price of MedAssets between 2007 and 2011. The company stock price declined between 2007 and 2008 from $23.94 to $14.60, which reveals more than 60% decline in the stock performances. However, the MedAssets stock price appreciated to $21.21 in 2009 and $20.19 in 2010.

Fig 1: MedAssets Stock Price in the last 5 years

Source: MedAssets (2012).

However, the company stock price declined to $9.25 in 2011 revealing 118% decline in the performances between 2010 and 2011. Data in Table 1 reveals how the company total returns deteriorated in the lat 4 years between 2008 and 2011. In 2008, the company total returns was -39% and the total returns deteriorated to -54.2% in 2011. However, the company stock performances compared to industry shows that the company stock performances are lower than industry stock performances. Table 1 reveals that the industry performances in 2008 were -17.4% compared to the company stock performances, which declined to -39.0% in 2008. However, the MedAssets stock performances were better than the industry performances in 2011.

In comparison with the market value, the market value was better in 2008 than the value of the company stock. However, at the end of 2011 fiscal year, the performances of the company stock and the market value deteriorated to the same level. Based on poor performances of the MedAssets stock in the last 4 years, the company did not pay dividends to shareholder at the end of the 2009 and 2010 fiscal years. (MedAssets Annual Report 2010).

Table 1: MedAssets Stock Performances






Total Returns %





+/- Market





+/- Industry





Market Capitalization (USD Million)






Return on Equity %





Return on Assets %





Net Margin %





Total Equity U.S.$ Million

Several factors led to the decline of MedAssets stock price in the last 4 years. First, the U.S. financial crisis that starts from 2008 led to the decline of stock performances of many companies. The financial crisis occurred because of the collapse of mortgage institution in the United States. Before 2008, the mortgage banking institutions offered loans to people with bad credit history due to high interest rates. However, in 2007, the interest rates declined and the issue led to the drastic decline in the mortgage value. Many homeowners were unable to repay their loans and the whole issue triggered the present U.S. financial crisis. The effect of the financial crisis is widely felt by the banking institutions because many banking institutions were short of liquidity. After 2008, the effect of the credit crunch is transferred to the non-banking institutions, and the stock price of many organizations deteriorated because of the present U.S. financial crisis. (Clare,2010). Likewise other corporate organizations, MedAssets stock showed a decline in performances in 2008. Although, the MedAssets stock price improved between 2009 and 2010, however, the company stock deteriorated in 2011. The stock price fell from $20.19 in 2010 to $9.25 in 2011 revealing 118% decline in the stock returns. Typically, MedAssets stock value has not yet recovered to its level of 2010. Presently, the company stock price is $12.33.

Another factor leading to the decline in the MedAssets stock returns is the market competitions. MedAssets is facing a stiff competition from several healthcare technology enabled providers. However, direct competitors of MedAssets are Accretive Health, Inc. Allscripts Healthcare Solutions, Inc. And McKesson Corporation. Data in Table 2 reveal that the MedAssets is behind its competitors with reference to their market capitalization. Additionally, Accretive Health, Inc. And Allscripts Healthcare Solutions, Inc. are ahead of MedAssets in term of the total revenue. The company is also lagging behind its competitors in the earning-per-share.

Table 2: MedAssets Direct Competitor Comparison

Direct Competitor Comparison

MedAssets, Inc.

Accretive Health, Inc.

Allscripts Healthcare Solutions, Inc.

McKesson Corporation


Market Capitalization:










Quarterly Rev Growth (yoy):






Revenue (ttm):



Gross Margin (ttm):






EBITDA (ttm):




Operating Margin (ttm):






Net Income (ttm):





Earning Per Share (ttm):






price-to-earnings (ttm):






price/earnings to growth (5-year expected):






Price to Sales ratio.






Source: Yahoo Finance (2012).

Overview of the MedAssets stock returns compared to S&P 500 index reveals that MedAssets stock does not generate stock returns compared to S&P 500 index. Data in Table 3 and Fig 2 reveal the three-year comparison of MedAssets stock returns and S&P 500 Index the comparison of the s MedAssets stock returns and S&P 500 index reveal that MedAssets relative performance is lower than S&P 500 index. Based on the 3-year annual return, the company records -9.98% and S&P 500 index records +15.26%.

Table 3: MedAssets stock returns compared to S&P 500 Index


S&P 500 Index

Year to Date (ytd) return



1 Yr Return:



3 Yr Ann. Return:



50 Day Moving Average:


Change of 50 Day Moving Average



200 Day Moving Average


Change of 200 Day Moving Average:



Source. Hedgeable, 2012.

Fig 2: MedAssets stock returns compared to S&P 500 Index

- MedAssets Inc. (MDAS)

- S&P 500 INDEX ($SPX)

- Healthcare

MedAssets Derivatives Implementation

To satisfy the company business operations, MedAssets raises a significant amount of loan bearing interests from banks. By December 2010, the company raised an outstanding borrowing that worth $635.0 million, and the term of loan bears the interest rates of 1.5% plus the applicable margin. Additionally, the company has issued outstanding principal amount of the company bond worth $325.0 million which carries the interest of 8% per annum. Bonds are the notes issued to raise fund from the public. Bonds are inform of debts because they carry interests and should be repaid when they reach their maturity. MedAssets issues long-term debt to raise fund from the public. The long-term debts are the financial obligation lasting more than one year, which a company must pay at its time of maturity. Other type of securities is the commercial paper, and short-term notes issued by the company. However, this kind of notes is… [END OF PREVIEW] . . . READ MORE

Two Ordering Options:

Which Option Should I Choose?
1.  Buy full paper (8 pages)Download Microsoft Word File

Download the perfectly formatted MS Word file!

- or -

2.  Write a NEW paper for me!✍🏻

We'll follow your exact instructions!
Chat with the writer 24/7.

Financial Analysis of Brocade Communications Systems, Inc Research Paper

Financial Analysis of International Airlines Group Thesis

Financial Analysis: Wal-Mart Research Paper

Financial Analysis Case Study

Financial Analysis of Estee Lauder Company Term Paper

View 200+ other related papers  >>

How to Cite "Financial Analysis of Medassets" Term Paper in a Bibliography:

APA Style

Financial Analysis of Medassets.  (2012, May 14).  Retrieved October 30, 2020, from

MLA Format

"Financial Analysis of Medassets."  14 May 2012.  Web.  30 October 2020. <>.

Chicago Style

"Financial Analysis of Medassets."  May 14, 2012.  Accessed October 30, 2020.